Share Price | LifeMD, Inc. Stock Analysis & Recommendation

Q: Is LifeMD, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for LifeMD, Inc. has changed from sideways to mildly bearish. The weekly MACD is bearish, while the monthly MACD is bullish, indicating mixed signals. The Bollinger Bands and KST are both mildly bearish on a weekly and monthly basis, and Dow Theory also reflects a mildly bearish stance. Daily moving averages show a mildly bullish trend. In terms of performance, LifeMD has outperformed the S&P 500 on a year-to-date basis with a return of 29.90% compared to the S&P 500's 12.22%, and over three years, it has significantly outperformed with a return of 179.57% against the S&P 500's 70.41%. Overall, the current technical stance is mildly bearish, with key indicators such as the weekly MACD and Bollinger Bands driving this view.

Q: What does LifeMD, Inc. do?

Overview: LifeMD, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 66 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 2 Million (Quarterly Results - Mar 2025) Market cap: USD 618.58 Million (Micro Cap)Key Metrics: Debt Equity: 6.65 Return on Equity: 436.41% Price to Book: -265.63Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Should I buy, sell or hold LifeMD, Inc.?

Based on the current analysis of LifeMD, Inc., it would be prudent to hold your position in the stock rather than buy or sell at this time. The company is facing challenges with a negative book value and weak long-term fundamental strength, highlighted by a significant decline in operating profit over the past five years. While there have been positive results in recent quarters, including a notable increase in net sales and operating profit, the overall growth remains concerning, especially with a negative EBIT to interest ratio indicating difficulties in servicing debt. Additionally, the stock is considered risky, trading at high valuations despite a lack of profit growth over the past year.On a positive note, the company has a strong institutional ownership at 53.14%, suggesting that more experienced investors are backing it. However, given the mixed signals and underlying weaknesses, holding your investment seems to be the most cautious approach for now.

Results Declared: LifeMD, Inc. has declared results on 05 Aug 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

373.91 k

Shareholding (Mar 2026)

FII

8.65%

Held by 49 FIIs

DII

90.85%

Held by 22 DIIs

Promoter

0.50%

Is LifeMD, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, LifeMD, Inc. shows a mildly bearish technical trend despite strong year-to-date and three-year performance, with mixed signals from indicators like the weekly MACD and Bollinger Bands.

View full answer

How big is LifeMD, Inc.?

22-Jun-2025

As of Jun 18, LifeMD, Inc. has a market capitalization of 618.58 million and reported net sales of 234.00 million with a net profit of -10.17 million over the latest four quarters. Shareholder's funds are at -5.49 million, and total assets amount to 72.46 million.

View full answer

What does LifeMD, Inc. do?

22-Jun-2025

LifeMD, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $66 million and a net profit of $2 million. It has a market cap of $618.58 million and notable financial metrics, including a debt equity ratio of 6.65 and a return on equity of 436.41%.

View full answer

Should I buy, sell or hold LifeMD, Inc.?

22-Jun-2025

Compare LifeMD, Inc. with Similar Stocks

CareMax, Inc.Talkspace, Inc.The Pennant Group, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a fall in Net Sales of -5.75%, the company declared Very Negative results in Jun 26

The company has declared negative results for the last 2 consecutive quarters
PRE-TAX PROFIT(Q) At USD -7.08 MM has Fallen at -106.11%
NET PROFIT(Q) At USD -7.08 MM has Fallen at -92.95%
OPERATING CASH FLOW(Y) Lowest at USD -9.92 MM

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 179 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.56

Return on Equity

-13.57%

Price to Book

7.72

Revenue and Profits:

Net Sales:

47 Million

(Quarterly Results - Jun 2026)

Net Profit:

-7 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-20.71%

6 Months

13.38%

1 Year

-46.14%

2 Years

-33.71%

3 Years

-9.18%

4 Years

34.85%

5 Years

-63.78%

LifeMD, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

44.50%

EBIT Growth (5y)

14.58%

EBIT to Interest (avg)

-23.04

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

6.65

Sales to Capital Employed (avg)

24.89

Tax Ratio

4.12%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

56.83%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

7.72

EV to EBIT

-99.74

EV to EBITDA

15.87

EV to Capital Employed

-10.99

EV to Sales

0.61

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-13.57%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 33 Schemes (19.11%)

Foreign Institutions

Held by 49 Foreign Institutions (8.65%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is -5.78% vs 7.04% in Mar 2026",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2026 is 20.22% vs -709.09% in Mar 2026",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'26",
        "Mar'26",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "47.30",
          "val2": "50.20",
          "chgp": "-5.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.10",
          "val2": "-6.90",
          "chgp": "26.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.10",
          "val2": "-8.90",
          "chgp": "20.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-150.80%",
          "val2": "-178.00%",
          "chgp": "2.72%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -8.66% vs 39.34% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 45.45% vs -5.06% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "194.10",
          "val2": "212.50",
          "chgp": "-8.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.40",
          "val2": "-6.70",
          "chgp": "94.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.40",
          "val2": "2.20",
          "chgp": "-36.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.20",
          "val2": "-18.70",
          "chgp": "45.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-39.50%",
          "val2": "-76.00%",
          "chgp": "3.65%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ

Jun'26

Mar'26

Change(%)

Net Sales

47.30

50.20

-5.78%

Operating Profit (PBDIT) excl Other Income

-5.10

-6.90

26.09%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.10

-8.90

20.22%

Operating Profit Margin (Excl OI)

-150.80%

-178.00%

2.72%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2026 is -5.78% vs 7.04% in Mar 2026

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2026 is 20.22% vs -709.09% in Mar 2026

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

194.10

212.50

-8.66%

Operating Profit (PBDIT) excl Other Income

-0.40

-6.70

94.03%

Interest

1.40

2.20

-36.36%

Exceptional Items

-1.20

0.00

Consolidate Net Profit

-10.20

-18.70

45.45%

Operating Profit Margin (Excl OI)

-39.50%

-76.00%

3.65%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -8.66% vs 39.34% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 45.45% vs -5.06% in Dec 2024

All Annual Results

Company CV

About LifeMD, Inc.

LifeMD, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available